載入...
Response to anti-EGFR therapy in patients with BRAF non-V600 mutant metastatic colorectal cancer
PURPOSE: While mutations in BRAF in metastatic colorectal cancer (mCRC) most commonly occur at the V600 amino acid, with the advent of next-generation sequencing, non-V600 BRAF mutations are increasingly identified in clinical practice. It is unclear whether these mutants, like BRAF V600E, confer re...
Na minha lista:
| 發表在: | Clin Cancer Res |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2019
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6891165/ https://ncbi.nlm.nih.gov/pubmed/31515458 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-2004 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|